Introduction
Aortic dissection, first described several centuries ago [1, 2] , remained a fatally catastrophic vascular event until the 1950s when pertinent surgical interventions were introduced [3] . Surgical repair of aortic dissection saved many lives but its high perioperative mortality left room for improvement [4] . Developments in medical devices and less invasive techniques led to significantly lower perioperative mortality and morbidity rates thanks to the introduction in 1999 of stent implantation to treat aortic dissection [5] [6] [7] . Currently, thoracic endovascular aortic repair (TEVAR) is recommended as first-line treatment for complicated type B aortic dissection [8] .
Aortic dissection entails the separation of aortic wall layers secondary to bleeding within and along the aortic wall through an intimal tear. Aortic dissection is most commonly classified based on anatomical features using the Stanford classification, with type A dissection involving the ascending aorta regardless of primary entry tear site, and type B dissection not involving it [9] . In hospital-based studies in western populations, the incidence of aortic dissection is 3-5 cases per 100,000 people per year, which is probably an underestimation because of omission of pre-admission deaths [10] [11] [12] . In population-based studies, aortic dissection incidence is higher, namely 15 cases in the western population and 43 cases in Asians per 100,000 per year, maybe reflecting a higher prevalence of hypertension among Asians [13] [14] [15] . The incidence can be even higher in the elderly population. In published studies, 20%-30% of aortic dissections are type B [11, 16] .
In TEVAR, stents are used to cover the primary entry tear and to support the collapsed intima. After stent implantation, blood flow is redirected towards the true lumen thereby alleviating malperfusion of branch arteries, while entry tear coverage lowers the risk for dissection aneurysm by reducing false lumen pressure. The latter advantages translate into improved safety and efficacy. In the international registry of aortic dissection (IRAD), in-hospital mortality was significantly lower for patients with type B aortic dissecton treated with TEVAR vs. surgically (11 patients [10.8%] vs. 26 patients [23%]), death rate at five years was significantly lower for patients who underwent endovascular treatment vs. medical management (15.5% vs. 29 .0%, respectively), moreover, descending aorta diameter at five years was significantly smaller after stent graft vs. medical therapy alone (median, 4.2 [interquartile: 3.8 to 5.2] cm vs. 4.6 [3.6 to 5.5] cm, respectively; p = 0.034) [16, 17] .
Researchers also have investigated the prognosis of type B aortic dissection. Syncope, hypotensive or shock, diameter ≥ 55 mm, and periaortic hematoma have been validated as risk factors for in-hospital mortality [18] . In clinical practice, not all patients who have undergone TEVAR show favorable aortic remodeling, and in addition to classic prognostic factors, such as the ocurrence of complications (spinal ischemia, mesenteric ischemia, acute renal failure, hypotension, and limb ischemia) and severe symptoms (hypotension or shock, syncope, refractory hypertension, and abdominal pain), imaging features have drawn increasing attention. However, studies involving imaging mostly have focused on common characteristics, such as aortic diameter, branch vessel While previous studies have provided insight into prognosis after TEVAR [23] [24] [25] , the Registry Of type B aortic dissection with the Utility of STent graft (ROBUST) will evaluate the evolving use and outcomes of TEVAR in a real-world setting. Furthermore, the registry will compare patients in different risk categories and may help identify which subgroup of patients would benefit the most from TEVAR.
Objective
The primary objective of the registry is to identify predisposing risk factors and prognostic factors for adverse events, in particular, adverse false lumen thrombosis after TEVAR in a real-world setting.
The secondary objectives are to: (1) generate more accurate indications for TEVAR by comparing patients in different risk-stratified subgroups; (2) assess the perioperative and long-term clinical outcomes of patients who have undergone and who are undergoing TEVAR; and (3) assess the perioperative and long-term outcomes of patients after different types of reinterventions.
Methods

Study design
The ROBUST study is an ambispective, multicenter, open cohort study. Participation is entirely voluntary and the data will be collected after discharge. We plan to recruit consecutive patients after TEVAR from 2008 to 2027. After enrolment, all patients will be advised to undergo computed tomography angiography (CTA) examination at 3, 6, and 12 months after intervention, and yearly thereafter. We will acquire the clinical information from electronic patient databases and the CTA DICOM files from Radiology Department databases. This registry is designed and initiated by the Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital. To increase generalizability of study results, we invited four additional participating centres across China with enough experience to join this study, i.e., each performing over 30 TEVAR yearly. The ROBUST study is an open project, and we welcome institutions fulfilling the specified requirements to join the study during the recruitment phase. The study has been registered in the Chinese Clinical Trial Registry under registration number ChiCTR-POC-17011726.
Participants
We will screen all patients who underwent TEVAR from January 1, 2008 to July 1, 2017, and will invite by phone patients with at least one follow-up timepoint to join our study.
All patients admitted to hospitals for TEVAR after July 1, 2017 will be included in our study regardless of age, gender and underlying disease to reflect real-world practice.
Recruitment is non-competitive and will not influence clinical practice.
Criteria
Inclusion criteria: 1) Patients who have undergone and who will undergo TEVAR for type B aortic dissection; 2) patients who agree to participate in the study.
Exclusion criteria: 1) patients for whom CT angiography would not be advisable (pregnant or preparing for pregnancy, lactating, or with chronic renal failure, or history of hypersensitivity to iodinated contrast media); 2) patients lacking a preoperative CT angiography file in DICOM format, or with images that are not amenable to reconstruction.
Data collection
A standard case report form (CRF) was designed at the beginning of our study. It will be used to obtain demographic information, disease history, surgical details, imaging features, and outcome events of participants. Data will be primarily recorded on paper CRFs, then two researchers will input the CRFs into an electronic database simultaneously in case of typing errors.
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Data elements
To address the objectives, we meticulously designed the CRF to collect the necessary information. The CRT consists of four parts, and the 184 variables compiled within the ROBUST study will include:
1. Demographics and disease history: Age, gender, height, weight, tobacco consumption, drinking habits, diabetes mellitus, hypertension, dyslipidaemia, ischemic stroke, coronary artery disease, carotid stenosis, and chronic obstructive pulmonary disease. 3. Preoperative imaging features: Periaortic hematoma, impending rupture, pleural effusion, dissection length, primary tear location, branch arteries involvement, distal outflow track status, false lumen thrombosis status, diameter of aorta, true lumen, and false lumen at different levels, volume of aorta, true lumen, and false lumen. 4. Outcomes: Periaortic hematoma, impending rupture, pleural effusion, proximal endoleak, stent-graft induced new entry, retrograde dissection, new reentry tear in lower thoracic aorta, number of intimal tears, branch arteries involvement, false lumen thrombosis status of stent-graft-covered segment, diameter of aorta, true lumen, and false lumen at different levels, volume of aorta, true lumen, and false lumen, ischemic stroke, myocardial infarction, arterial embolism in lower limbs, paraplegia, and death.
Sample size and statistical analysis
Scant data are available on prognostic factors for thoracic aortic remodeling. Based on our previous study [26] , we calculated the sample size using effect of branches number 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   8 from thoracic false lumen on thoracic aortic remodeling. A minimum sample size of 196 patients will be included with a two-sided significance level of 5% and a power over 0.8.
Because the recruitment phase will continue until 2027, the number participants of this study is expected to well exceed 196.
The results will be presented as frequencies and percentages for categorical variables, and as means and standard deviations for continuous variables. The different outcomes will be compared with the use of the chi-square test for categorical variables and the Mann-Whitney test for continuous variables. Association between variables and outcomes first will be assessed by univariate regression analysis. After reviewing the variables for clinical significance, a subsequent Cox proportional-hazards analysis will be used to identify independent predictors of primary outcomes. Stratification analysis will be performed to identify which subgroup of patients would benefit the most from TEVAR.
Ethics and dissemination
The protocol has been approved by the ethics committee of the coordinating centre. This study was designed as an ambispective, observational registry, and the information will be collected after discharge. Therefore, clinical practice will not be influenced by the study. For patients admitted to hospitals for TEVAR before July 1, 2017, we will call them for verbal agreement. Signed informed consent will be obtained from patients admitted to hospitals after July 1, 2017. The present study will be conducted in accordance with the provisions of the Declaration of Helsinki.
As soon as we fill out the CRFs, we will transfer them to an electronic database which will be stored both in a cloud environment and in a hard disk. Result dissemination is expected to commence in 2018 in professional peer-reviewed journals to promote understanding of the rehabilitation process. 
Authors' contributions
Interventions 11a
Interventions for each group with sufficient detail to allow replication, including how and when they will be administered _____NA____ _ 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) _____NA____ _ 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
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Participant timeline 13
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Ethics and dissemination:
The protocol has been approved by the ethics committee 37 of the coordinating centre. Findings will be disseminated in professional peer-reviewed 38 journals to promote understanding of the rehabilitation process. 39 
Trial registration number: This study is registered in the Chinese Clinical Trial
40
Registry (registration number: ChiCTR-POC-17011726). 41
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